ARIX BIOSCIENCE PLC — Report Publication Announcement 2017

Sep 18, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9654Q

Arix Bioscience Plc

18 September 2017

Arix Bioscience hosts Capital Markets Meeting today

LONDON, 18 September, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "Arix"), a global healthcare and life science company supporting medical innovation, is today hosting its inaugural Capital Markets Meeting for investors and analysts in London.

Joe Anderson, Chief Executive Officer, and Jonathan Peacock, Chairman, will provide an update on Arix Bioscience's strategy and progress to date. The event will also include presentations from additional members of the Arix Bioscience team as well as a number of Arix Group Businesses, who will each provide a detailed overview of their respective companies, objectives and potential.

The meeting will be held at Etc. Venues 8 Fenchurch Place, Fenchurch Street, London EC3M 4PB, from 12:30 to 18:00 BST. The event will start with an informal lunch buffet, followed by a series of short presentations, question-and-answer sessions and networking. No new material information will be disclosed.

Presenters at the Arix Capital Markets Meeting will include:

·     Joe Anderson, PhD, CEO of Arix Bioscience plc

·     Jonathan Peacock, Chairman of Arix Bioscience plc

·     Daniel O'Connell, MD, PhD, Arix Bioscience plc

·     Mark Chin, Arix Bioscience plc

·     Christian Itin, PhD, CEO and Chairman of Autolus

·     Niall Martin, PhD, CEO of Artios Pharma

·     Jerry McMahon, PhD, President and CEO of Harpoon Therapeutics

·     Corey Fishman, MSM, CEO of Iterum Therapeutics

·     Gordon Hamilton, MA MD MBBS MBA, CEO of Depixus

·     Mike Moran, MBE, CEO of Proton Partners International

A live webcast of the event, with presentation slides, will be available on the Arix website at:  https://edge.media-server.com/m6/p/2ypqux2r.  A replay will be available on the website shortly after the event.

Ends

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

+44 (0)20 7290 1052

Matthew Cole, Communications Director

+44 (0)20 7290 1065

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGUQUBUPMPUM